PE-22-28 - Seenergie

PE-22-28

Promotes the creation of new nerve cells and neural connections to alleviate depression with fewer side effects.

Active ingredient:

n/a

Molecular formula:

C35H55N11O9

Molecular weight:

773.9 g/mol

Intake:

Nasal

PE-22-28

Promotes the creation of new nerve cells and neural connections to alleviate depression with fewer side effects.

Active ingredient:

n/a

Molecular formula:

C35H55N11O9

Molecular weight:

773.9 g/mol

Intake:

Nasal

What is

PE-22-28

PE-22-28 represents a highly effective solution for depression, serving as a robust catalyst for the creation of new nerve cells (neurogenesis) and the formation of new neural connections (synaptogenesis) in the hippocampus. In comparison to existing antidepressant medications, it exhibits notably fewer side effects. It demonstrates a remarkable capacity to inhibit TREK-1, a channel protein associated with mood regulation, even after undergoing modifications to enhance its half-life or change the method of administration.

In essence, PE-22-28 stands as a promising focus for shaping the development of a new wave of antidepressants, while also contributing to the evolving realm of nootropics. Moreover, it plays a role in broadening the range of therapeutic options for managing neurodegenerative conditions like Alzheimer’s disease.

Benefits

Alleviates depression

Enhances the process of neurogenesis

Assists in post-stroke depression (PSD)

Protocols

Provided as a 400 mcg/spray (0.1 ml) nasal spray

Initiation: PE-22-28 therapy is initiated to support neuroprotection, cognitive function, and mental health by modulating neurotrophic factors and neurotransmitter systems.

Initial Dose: Begin with 1 spray (400 mcg) in each nostril once daily (OD) during the daytime for the first two weeks to assess tolerance and minimize potential side effects.

Titration: If well tolerated, continue with the dose of 1 spray (400 mcg) in each nostril once daily (OD) during the daytime after the initial two-week period.

Maintenance: Maintain the dose at 1 spray (400 mcg) in each nostril once daily for ongoing support in neuroprotection and cognitive function.

Duration: PE-22-28 is administered daily.

Weeks 1-2: 1 spray (400 mcg) in each nostril once daily during the daytime

Week 3 and onwards: 1 spray (400 mcg) in each nostril once daily during the daytime

Provided as a standard protocol, dose may vary depending on the condition of the patient.
The dosage of PE-22-28 may be adjusted based on the individual’s response, medical history, and specific treatment goals.

Known hypersensitivity to PE-22-28 or any component of the formulation.

Not recommended for use during pregnancy or breastfeeding unless specifically advised by a healthcare provider.

Patients with severe nasal or sinus conditions should consult with their healthcare provider before starting this treatment.

Avoid using other nasal medications concurrently without professional advice to prevent potential interactions.

Regular monitoring of cognitive function and overall mental health to assess the effectiveness of the treatment.

Periodic assessments to check for any adverse effects and to adjust the treatment as necessary.

Consultation with a healthcare professional before starting PE-22-28 to ensure it is appropriate for the patient’s health condition.

Patients should maintain a healthy lifestyle, including proper diet and exercise, to support the effectiveness of the treatment.

Procedure

Shake the nasal spray bottle gently before use.

Remove the cap from the nasal spray bottle.

Insert the nozzle into one nostril and close the other nostril with a finger.

Press down on the pump to release 1 spray (400 mcg) while inhaling gently through the nose.

Repeat the process for the other nostril.

Administer the spray once daily as prescribed.

Do not exceed the recommended dosage unless advised by a healthcare provider.

Store the nasal spray bottle in a cool, dry place away from direct sunlight.

Ensure the bottle is tightly sealed to maintain the integrity of the solution.

Keep out of reach of children.

Monitor for any unusual symptoms and report them to a healthcare provider immediately.

Clinical Research

Study:

PE-22-28 Nasal Peptide for Depression and Neurogenesis

Source:

Core Peptides, Biotech Peptides, Peptides Calculator

Results:

PE-22-28 is a synthetic derivative of the naturally occurring peptide spadin, and it has shown significant potential in treating depression and enhancing neurogenesis. Administered nasally, PE-22-28 effectively crosses the blood-brain barrier and targets the central nervous system.

PE-22-28 acts as a blocker of the TREK-1 channel, a potassium channel implicated in the regulation of mood and neuroplasticity. By inhibiting TREK-1, PE-22-28 enhances serotonin transmission, promotes neurogenesis, and increases synaptogenesis in the hippocampus. This action is crucial for improving mood, cognitive function, and overall brain health. The peptide also upregulates brain-derived neurotrophic factor (BDNF), which supports the survival of existing neurons and encourages the growth of new neurons and synapses.

Core Peptides, 2023; Biotech Peptides, 2023; Peptides Calculator, 2023.

Read More: https://www.corepeptides.com/, https://www.biotechpeptides.com/, https://www.peptidescalculator.com/

Articles

PE-22-28 Peptide: A Peptide with Multifaceted Potential

In the realm of biomedical research, peptides have garnered significant attention due to their versatility in various therapeutic applications. One such peptide that has been the subject of growing interest is PE-22-28, a promising compound that has shown great potential in addressing numerous health challenges.

PE-22-28 Peptide: Depression and Neurogenesis.

Studies suggest that PE-22-28 may bind to TREK-1, a manufactured version of the naturally occurring peptide spadin. TREK-1 is localized to brain areas that regulate emotion, memory, and cognition. Researchers are looking at PE-22-28 for a variety of research applications, including within the context of depression and cognitive ability, stroke recovery aid, and in the […]

Doctor's Reviews

Selank, Semax, PE 22-28

PE-22-28 is a synthetic peptide derived from Spadin, addressing major depressive disorder by blocking the TREK-1 channel in the central nervous system.

What you need to know about PE-22-28 Peptide | Peptide | San Diego Wellness Lounge

PE-22-28 peptide is a newly discovered peptide that has gained attention among researchers, healthcare professionals, and individuals seeking to enhance their neurological functions.